Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27110142
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Managing mitral regurgitation: focus on the MitraClip device
#MMPMID27110142
Magruder JT
; Crawford TC
; Grimm JC
; Fredi JL
; Shah AS
Med Devices (Auckl)
2016[]; 9
(?): 53-60
PMID27110142
show ga
Based on the principle of surgical edge-to-edge mitral valve repair (MVR), the
MitraClip percutaneous MVR technique has emerged as a minimally invasive option
for MVR. This catheter-based system has been widely demonstrated to be safe,
although inferior to surgical MVR. Studies examining patients with ?3+ mitral
regurgitation (MR) show that, for all patients treated, freedom from death,
surgery, or MR ?3+ is in the 75%-80% range 1 year following MitraClip
implantation. Despite its inferiority to surgical therapy, in high-risk surgical
patients, data suggest that the MitraClip system can be employed safely and that
it can result in symptomatic improvement in the majority of patients, while not
precluding future surgical options. MitraClip therapy also appears to reduce
heart failure readmissions in the high-risk cohort, which may lead to an economic
benefit. Ongoing study is needed to clarify the impact of percutaneous mitral
valve clipping on long-term survival in high-risk populations, as well as its
role in other patient populations, such as those with functional MR.
free
free
free
